Literature DB >> 11684313

Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1).

Koushi Yamaguchi1, Mitsuo Honda, Hajime Ikigai, Yukihiko Hara, Tadakatsu Shimamura.   

Abstract

Epigallocatechin gallate (EGCg), the major tea catechin, is known as a potent anti-bacterial agent. In addition, anti-tumor promoting, anti-inflammatory, anti-oxidative and antiviral activities have been reported. In the present study, we investigated possible anti-human immunodeficiency virus type-1 (HIV-1) activity of EGCg and its mechanisms of action in the viral life cycle. EGCg impinges on each step of the HIV life cycle. Thus, destruction of the viral particles, viral attachment to cells, post-adsorption entry into cells, reverse transcription (RT), viral production from chronically-infected cells, and the level of expression of viral mRNA, were analyzed using T-lymphoid (H9) and monocytoid (THP-1) cell systems, and antiviral protease activity was measured using a cell-free assay. Inhibitory effects of EGCg on specific binding of the virions to the cellular surfaces and changes in the steady state viral regulation (mRNA expression) due to EGCg were not observed. However, EGCg had a destructive effect on the viral particles, and post-adsorption entry and RT in acutely infected monocytoid cells were significantly inhibited at concentrations of EGCg greater than 1 microM, and protease kinetics were suppressed at a concentration higher than 10 microM in the cell-free study. Viral production by THP-1 cells chronically-infected with HIV-1 was also inhibited in a dose-dependent manner and the inhibitory effect was enhanced by liposome modification of EGCg. As expected, increased viral mRNA production was observed in lipopolysaccharide (LPS)-activated chronically HIV-1-infected cells. This production was significantly inhibited by EGCg treatment of THP-1 cells. In contrast, production of HIV-1 viral mRNA in unstimulated or LPS-stimulated T-lymphoid cells (H9) was not inhibited by EGCg. Anti-HIV viral activity of EGCg may thus result from an interaction with several steps in the HIV-1 life cycle.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11684313     DOI: 10.1016/s0166-3542(01)00189-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  46 in total

1.  Tea polyphenols exerts anti-hepatitis B virus effects in a stably HBV-transfected cell line.

Authors:  Pian Ye; Shuling Zhang; Lei Zhao; Jihua Dong; Shenghua Jie; Ran Pang; Shuli Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

2.  Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro.

Authors:  Jing-yao Pang; Kui-jun Zhao; Jia-bo Wang; Zhi-jie Ma; Xiao-he Xiao
Journal:  J Zhejiang Univ Sci B       Date:  2014-06       Impact factor: 3.066

3.  A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans.

Authors:  Che C Colpitts; Luis M Schang
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

4.  Epigallocatechin Gallate Inhibits Macaque SEVI-Mediated Enhancement of SIV or SHIV Infection.

Authors:  Run-Hong Zhou; Le Guo; Jin-Biao Liu; Hang Liu; Wei Hou; Tong-Cui Ma; Xu Wang; Jian-Guo Wu; Li Ye; Wen-Zhe Ho; Jie-Liang Li
Journal:  J Acquir Immune Defic Syndr       Date:  2017-06-01       Impact factor: 3.731

5.  Effect of Sinecatechins on HPV-Activated Cell Growth and Induction of Apoptosis.

Authors:  Stephen K Tyring
Journal:  J Clin Aesthet Dermatol       Date:  2012-02

Review 6.  Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea.

Authors:  J Steinmann; J Buer; T Pietschmann; E Steinmann
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

7.  The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection.

Authors:  Ilona Hauber; Heinrich Hohenberg; Barbara Holstermann; Werner Hunstein; Joachim Hauber
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

8.  Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy.

Authors:  Christina L Nance; Edward B Siwak; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-02       Impact factor: 10.793

Review 9.  Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

Authors:  Mark J Ferris; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

Review 10.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.